Literature DB >> 36118411

GnRH Antagonist: a New and an Effective Way of Treatment of Advanced Prostate Cancer.

Bertrand Tomabal1, S K Raghunath2, N Srivatsa2, V H Nagaraj2.   

Abstract

Castration remains the mainstay of treatment in the management of metastatic prostate cancer. Medical castration plays an important role in a majority of these patients. Gonadotropin releasing hormone (GnRH) agonists have been commonly used hitherto to achieve medical castration. Arrival of GnRH antagonists have opened a new approach in the management of these patients with distinct drug-related and cancer-related benefits including prevention of microsurges and reduction in cardiovascular complications. This article elucidates the mechanism of action of GnRH antagonists along with its clinical advantages and demerits. © Indian Association of Surgical Oncology 2017.

Entities:  

Keywords:  Cardiovascular morbidity in metastatic prostate cancer; Degarelix; Gonadotropin releasing hormone antagonists; Metastatic prostate cancer; Microsurges

Year:  2017        PMID： 36118411      PMCID： PMC9478057          DOI： 10.1007/s13193-016-0611-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  17 in total

Review 1.  Degarelix: a review of its use in patients with prostate cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

2.  Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Authors:  Matthew R Smith; Laurence Klotz; Egbert van der Meulen; Enrico Colli; László B Tankó
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

3.  Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.

Authors:  J de la Rosette; R Davis; D Frankel; T Kold Olesen
Journal:  Int J Clin Pract       Date:  2011-02-22       Impact factor: 2.503

4.  The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Authors:  Seiichiro Ozono; Takeshi Ueda; Senji Hoshi; Akito Yamaguchi; Hideki Maeda; Yuji Fukuyama; Kentaro Takeda; Yasuo Ohashi; Taiji Tsukamoto; Seiji Naito; Hideyuki Akaza
Journal:  Jpn J Clin Oncol       Date:  2012-03-28       Impact factor: 3.019

5.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Authors:  Matthew R Smith; Laurence Klotz; Bo-Eric Persson; Tine Kold Olesen; Arthur A M Wilde
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 6.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

Authors:  Jörg B Engel; Andrew V Schally
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

7.  Degarelix: a new approach for the treatment of prostate cancer.

Authors:  Bo-Eric Persson; Tine Kold Olesen; Jens-Kristian Jensen
Journal:  Neuroendocrinology       Date:  2009-07-14       Impact factor: 4.914

8.  Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.

Authors:  J Pinski; T Yano; G Miller; A V Schally
Journal:  Prostate       Date:  1992       Impact factor: 4.104

9.  The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Authors:  Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder
Journal:  BJU Int       Date:  2008-12       Impact factor: 5.588

10.  Degarelix.

Authors:  James E Frampton; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.